Safety and Efficacy of Chula High Flow Nasal Cannula

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210825007

Enrollment

Registered

2021-08-25

Start date

2021-08-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phase 1 Healthy group Phase 2 COVID-19 with respiratory failure High flow nasal cannula COVID-19 Acute respiratory failure Pneumonia

Interventions

Innovated Chula High Flow Nasal Cannula

Experimental Device

Chula HFNC

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Phase 1: Healthy subjects (N=5) Phase 2: COVID-19 pneumonia with respiratory failure (PF ratio 150-300 or SpO2 <90-94% while using conventional oxygen therapy) for at least 2 hours or met other criteria to use HFNC (N=10)

Exclusion criteria

Exclusion criteria: Phase 1: 1. underlying significant cardiopulmonary disease 2. unable to communicate Phase 2: 1. signs of respiratory failure (RR>40) or use accessory muscles 2. met criteria for intubation including PF ratio<50, unable to protect airway, mental status change, unstable hemodynamic, reduction in glasgow coma scale<10

Design outcomes

Primary

Measure	Time frame
Oxygen parameters (phase 1) 2 hrs pulse oximeter, clinical evaluation,Rox index (phase 2) 2 hrs pulse oximeter, clinical evaluation	—

Secondary

Measure	Time frame
Side effects 2 hrs clinical evaluation	—

Countries

Thailand

Contacts

Public ContactNaricha Chirakalwasan

King Chulalongkorn Memorial Hospital

narichac@hotmail.com66849629502

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026